The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Analysts expect the S&P 500 to rise 7.5% over the next year, according to a recent analysis of stock price targets. Wall ...

Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to read an analysis of REGN stock now.

Regeneron will announce Q2 2025 results on August 1, 2025, and host a conference call at 8:30 AM ET. Regeneron Pharmaceuticals, Inc. announced that it will disclose its second quarter 2025 ...

Buying $100 In REGN: If an investor had bought $100 of REGN stock 20 years ago, it would be worth $6,185.92 today based on a price of $509.72 for REGN at the time of writing.

Regeneron launches a $200 million matching donation program for Good Days’ Retinal Disease Fund to enhance patient access to medicines.

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results.

Shares of Regeneron Pharmaceuticals Inc. REGN slid 2.64% to $508.86 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.84 ...